Background: The development of strategies that could not only efficiently detect the onset of Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disorder with no cure but also predict its development and evaluate therapeutic intervention would be of great value. In this respect, the metabolic status of ALS patients has called attention. Hence, this study aimed to investigate the potential correlation between changes in ALS’s metabolic parameters with the disease outcome in a systematic review.

Methods: The manuscripts were manually searched within different databases (PubMed, Web of Science and Cochrane). The inclusion criteria were original articles and reviews about individuals with ALS and its survival, disease prognosis and metabolism (weight, cholesterol, hypertension, BMI, and glycaemia). The authors also established three different exclusion criteria: studies including ALS and other degenerative disorders, works including animal models and published before the year 2000.

Results: In total, 29 papers were selected. From all manuscripts, only 82.8% ensured the participation of sALS patients. Also, 27.6% of selected studies described the presence of a genetic mutation. Regarding ALS prognosis, patient’s age, the age of ALS onset, ALS duration and survival, <50% of the papers addressed these issues. Specifically, regarding metabolism, 65.5% of articles mentioned BMI, 20.7% mentioned any data concerning hypertension, 6.89% cardiovascular risk, 10.3% obesity, 13.78% diabetes and 10.3% glycaemia. Concerning lipid metabolism, more results were gathered, but still, they did not suffice to establish a correlation with ALS development.

Conclusions: Altogether, the authors concluded that available information is not enough to establish a link between ALS and metabolism. In reality, less than half of the manuscripts evaluated show an association between both factors. Nonetheless, it is worth mentioning that metabolism does influence ALS, but not in a unique manner. There is a debate about patients’ hypo- and hypermetabolism. Thus, to provide a reliable record, a public policy in which all research and clinical centers might assess the parameters discussed herein is suggested. Accordingly, this systematic review attempts to provide a comprehensible database to facilitate mult centered collaboration, validation, and clinical translation.

Keywords: amyotrophic lateral sclerosis, patients, metabolism, prognostic factor, systematic review
INTRODUCTION

The Amyotrophic Lateral Sclerosis (ALS) is a progressive and fatal neurodegenerative disorder (1–3). ALS, also known as Lou Gehrig’s disease, has an incidence of 2.5 cases per 100,000 people/year and a prevalence of 4–6:100,000; definitely, it is the most common motor neuron disorder (4). Therefore, ALS has not being considered a rare disease once its developing risk is 1/400-1/700 (5). Currently, it is well-known for the involvement of more than 24 genes in ALS. However, these mutations account for 68% of familial cases (fALS) and just for 11% of sporadic ALS (sALS) (6). Oddly, 90% of all ALS cases are sporadic. ALS onset, regardless of its form, occurs in the fifth decade of life. The survival rate is 3–5 years after diagnosis, being men more affected than women (1.5:1) (7).

Along ALS occurs a specific and progressive degeneration of upper motor neurons of the corticospinal tract, motor cortex, and motor neurons from the lower brainstem and spinal cord (8–12). However, ALS is a multifactorial disorder and, consequently, not only neurons are afflicted, but also it presents reactive astrocytes, dysfunctional oligodendrocytes and activated microglia committed (13–20). Moreover, several mechanisms seem to be related to the onset and the evolution of ALS, including excitotoxicity, oxidative stress, mitochondrial dysfunction, protein aggregation, genetic mutations, diminishment in the axonal transport, modifications in RNA metabolism, and neuroinflammation (21–32).

Notably, there is neither a cure for ALS, nor even an effective therapy, although there are drugs used to attenuate ALS’ symptoms and bring significant benefits to patients, such as antioxidants, anti-inflammatory, antiapoptotic, and anticytotoxic agents (4, 25, 33). To date, one of the most used medications in the USA is Rilutek™ (riluzole), a glutamate release inhibitor (34). Several clinical trials have demonstrated an increase in the survival rate of ALS patients after Rilutek™ (35–37). More recently, the U.S. Food and Drug Administration (FDA) approved Radicava™ (edaravone), a powerful antioxidant that is not restricted to eliminate hydroxyl radicals and reactive oxygen but counteracts the increase in prostacyclin production (38). Because these new findings are promising, attention has been focused on prognostic factors and biomarkers for ALS. Indeed, biomarkers discovery may enable a reliable diagnosis and a predictable follow-up; nowadays, ALS’s diagnosis and prognosis are mainly based on physical exams (39). Furthermore, the discrepancies of signs among patients interpret clinical trials somewhat dubious (40).

A variety of clinical prognostic factors and several ALS-related biological biomarkers have been listed (41–45), including some associated with metabolism (42–58). With interest, metabolic changes in ALS animal models were also observed (46, 59–61). However, there is no consensus on whether these metabolic parameters are indeed related to the disorder prognosis itself or just represent a specific dataset from a single-center and population. In this context, lipid content, cholesterol, and BMI are often contradicting.

![Keywords of interest](image-url)

**FIGURE 1** | Inclusion criteria used to define the articles that would be evaluated and submitted to this systematic review.
Additionally, genetic mutation, glycaemia, hypertension, TGL, LDL, HDL, and even medication are seldom mentioned in ALS manuscripts, which make it more difficult to collect clinical investigation outcomes.

Thus, to investigate the potential correlation of metabolic status with ALS’s outcome and survival, authors have decided to put together recent data regarding BMI, hypertension, cardiovascular risk, obesity, diabetic, glycaemia, hyperlipidaemia, triglycerides (TGL), LDL, HDL, and cholesterol. In addition, further information directly and indirectly related to metabolism were included, such as the age of onset, smoking habits, disease duration (years), survival (years), population/ethnic group, mutation, family members with ALS (%), family members with motor disorders (n), first motor signs (%), ALSFRS and ALS medication (including medicine intake period). Therefore, this study presents a systematic review regarding the possible relationship between ALS subjects’ survival and the course of the disease, with metabolic-related factors.

**METHODS**

**Eligibility Criteria**

To perform our systematic review, we established inclusions and exclusion criteria. Clear inclusion criteria were original articles and reviews concerning ALS patients and their survival, disease prognosis and metabolism (Figure 1). Five different exclusion criteria were endorsed: (i) studies including ALS and other degenerative disorders, such as Alzheimer disease, Frontotemporal dementia, Myotonic Dystrophy, and Muscular Atrophy, (ii) articles including animal models, (iii) manuscripts published before the year 2000, due to the fact that several papers are issued every year, and epidemiology approaches and biochemical methodologies are constantly changing. Importantly, authors also excluded, (iv) studies in which there is a mix of ALS-FDT patients and ALS-AD subjects without any kind of discrimination, and (v) articles that despite having the keyword of our research is about guidance on the management and care of ALS patients (Figure 2).

![FIGURE 2](image_url) | Exclusion criteria used to define the articles that would be evaluated and submitted to this systematic review.
Search Strategy

The keywords and expression of interest were manually searched in various databases, i.e., PubMed, Web of Science and Cochrane. The databanks were selected for topics assurance and for including journals of authors’ interest. Specifically, the following strategy was used to establish the inclusion/exclusion criteria: (i) “Amyotrophic Lateral Sclerosis” (not the term ALS) AND “patient” AND “cohort” AND “mutation” AND “mitochondria” OR “metabolism”; (ii) Amyotrophic Lateral Sclerosis AND “patient” AND “cohort” AND “aging” AND “mitochondria” OR “metabolism”; (iii) “Amyotrophic Lateral Sclerosis” AND “patient” AND “cohort” AND “mutation” AND “glycaemia” OR “hypertension” OR “weight” OR “cholesterol”; (iv) “Amyotrophic Lateral Sclerosis” AND “patient” AND “cohort” AND “aging” AND “glycaemia” OR “hypertension” OR “weight” OR “cholesterol”; (v) “Amyotrophic Lateral Sclerosis” AND “patient” AND “cohort” AND “aging” AND “glycaemia” OR “hypertension” OR “weight” OR “cholesterol” AND “metabolism” OR “mitochondria”; (vi) “Amyotrophic Lateral Sclerosis” AND “patient” AND “cohort” AND “mutation” AND “glycaemia” OR “hypertension” OR “weight” OR “cholesterol” AND “metabolism” OR “mitochondria”;

TABLE 1 | Number of ALS patients per study, the percentage of SALs and F ALs patients, and the distribution of ALS subjects between sex in general population [male (M)/female (F) ratio].

| References | Total of ALS patients (n) | ALSf patients (n) | ALSs patients (n) | Male (M)/Female (F) (%) | (ratio) |
|------------|--------------------------|------------------|------------------|------------------------|--------|
| Chaussenot et al. (62) | 106 | 26 | 80 | N/A | |
| Chiò et al. (48, 49) | 658 | N/A | N/A | 50.7 (M)/49.3 (F) (1:1) | |
| Chiò et al. (41) | 638 | N/A | N/A | 55.2 (M)/44.8 (F) (1.2:1) | |
| Dedic et al. (63) | 82 | all excluded | 82 | 46.2 (M)/53.8 (F) (0.85:1) | |
| Delaye et al. (64) | 30 | N/A | N/A | 50 (M)/50 (F) (1:1) | |
| Dorst et al. (43) | 486 | 16 | 470 | 80.3 (M)/19.7 (F) (4:1) | |
| Dupuis et al. (42) | 369 | N/A | N/A | 52 (M)/40 (F) (1.3:1) | |
| Golomb et al. (65) | 10 | N/A | N/A | 60 (M)/40 (F) (1.5:1) | |
| Hollinger et al. (66) | 1,439 | N/A | N/A | 58.3 (M)/41.7 (F) (1.4:1) | |
| Huang et al. (67) | 413 | All excluded | 413 | 62 (M)/38 (F) (1.6:1) | |
| Huisman et al. (63) | 674 | All excluded | 674 | 65 (M)/35 (F) (1.8:1) | |
| Kasarskis et al. (69) | 80 | N/A | N/A | 56 (M)/44 (F) (1.3:1) | |
| Korner et al. (70) | 514 | N/A | N/A | 71 (M)/29 (F) (2.4:1) | |
| Li et al. (71) | 294 | 23 | 271 | 51.2 (M)/48.8 (F) (1.1:1) | |
| Mandrioli et al. (72) | 2,354 | 138 | 2216 | 61.7 (M)/38.3 (F) (1.6:1) | |
| Mandrioli et al. (73) | 275 | N/A | N/A | 61.7 (M)/38.3 (F) (1.6:1) | |
| Mariosa et al. (74) | 636,132 | N/A | N/A | 57 (M)/43 (F) (1.3:1) | |
| Millecamps et al. (75) | 162 | All excluded | 162 | 61.7 (M)/38.3 (F) (1.6:1) | |
| Miller et al. (76) | 21 | 21 | All excluded | N/A | |
| Moglia et al. (77) | 650 | 39 | 617 | 55.4 (M)/44.6 (F) (1.2:1) | |
| Moreau et al. (78) | 120 | N/A | N/A | 56 (M)/46 (F) (1.2:1) | |
| Mouzat et al. (79) | 438 | N/A | N/A | 56.1 (M)/43.9 (F) (1.3:1) | |
| Nieves et al. (80) | 302 | N/A | N/A | 58.9 (M)/41.1 (F) (1.4:1) | |
| Nunes et al. (81) | 37 | N/A | N/A | 48.6 (M)/51.4 (F) (0.9:1) | |
| Rafiq et al. (82) | 512 | 17 | 495 | 64.6 (M)/35.4 (F) (1.8:1) | |
| Shefner et al. (83) | 13 (placebo) | N/A | N/A | 54 (M)/46 (F) (1.2:1) | |
| Sutedja et al. (51) | 334–303 | All excluded | 334–303 | 57 (M)/43 (F) (1.3:1) | |
| Zinman et al. (84) | 164 | N/A | N/A | 60 (M)/40 (F) (1.5:1) | |
| Wei et al. (85) | 450 | All excluded | 450 | 57.9 (M)/42.1 (F) (1.4:1) | |
Risk of Bias

The authors did not perform any assessment for the risk of bias. Such tools are used mainly for randomized controlled trials (RCTs), and consequently, this tool would not be appropriate. As an alternative, data was collected and the limitation of each study was recorded. The results are presented herein.

Statistical Analysis

Results for descriptive analyses were expressed in absolute numbers (n) and percentages (%), and the data acquired were demonstrated in different tables. No sufficient data were gathered to perform a meaningful meta-analysis.

RESULTS

The search resulted in the collection of 924 manuscripts from PubMed, 54 from Web of Science and 52 from Cochrane (including original articles and reviews). After applying inclusion and exclusion criteria (Figures 1, 2), followed by a more in-depth and comprehensive evaluation of the pre-selected articles, 29 articles were considered for the study. Tables 1–8 summarize the collected data. As we can observe, from all manuscripts, 17.2% excluded fALS patients, which means that 82.8% of all articles ensured the participation of sALS subjects only. Besides, 93.1% of the studies reported M/F ratio. Despite the significant percentage of studies mentioning this parameter, discrepancies among reported M/F were noticed (Table 1).

To better understand ALS prognosis, information regarding fALS and mutations were assembled; amongst which, the most cited were SOD1, FUS, TARDBP, VAPB, ANG, C9or72, and CHCHD10 (Table 2). However, only 62.5% of the articles certified the inclusion of fALS patients only (27.6% of all selected studies described the genetic mutation).

To further evaluate ALS symptoms, as well as ALS prognosis, patient’s age, the age of ALS onset, ALS duration, and survival, data were tabulated in Table 3. The authors could observe that 58.6% of the manuscripts specified the age of ALS onset (mean 59.8 years). For ALS duration and survival, 31 and 44.8% of studies, respectively, addressed this issue. Precisely, the mean of ALS duration is about 2.15 years, while the mean of ALS survival is 2.88 years. Moreover, to investigate the influence of ethnicity on ALS prognosis, few data were acquired; only two studies mentioned the word “caucasian” and only one mentioned the word “white.” No information is known regarding the socioeconomic status of ALS individuals.

Considering that the motor symptoms’ onset, as well as ALS’s phenotypic features, can be related to the disease development and brain pathology, first motor signs and ALSFRS-R were also evaluated (Table 4). The most prevalent motor alteration among ALS patients was related to the upper or lower limbs (71.66%), followed by symptoms occurring at the bulbar level (28%). Specifically, about monitoring ALS progression, 48.3% of the studies used ALSFRS-R; the mean ratio of it was 36.4.

Concerning smoking habits (Table 5), only 17.2% of the evaluated manuscripts pointed out this factor among individuals with ALS. Explicitly, just one study excluded all smokers from statistics. About metabolism (Tables 5, 6), 65.5% of articles...
### Table 3

El Escorial and general data of ALS patients: age, age of onset (symptoms), disease duration (years), survival (years), population/ethnic group, and socio-economic status.

| References          | El Escorial | Age (years) | Age of onset | Disease duration (years) | Survival (years) | Ethnic group | Socio-economic status |
|---------------------|-------------|-------------|--------------|--------------------------|------------------|--------------|-----------------------|
| Chaussenot et al.   | Yes         | 65.6        | 62.4         | N/A                      | N/A              | French       | N/A                   |
| Chiò et al. (48, 49)| Yes         | N/A         | 61.8         | N/A                      | N/A              | Italian      | N/A                   |
| Chiò et al. (41)    | Yes         | N/A         | 66.3         | N/A                      | 1.7              | Italian      | N/A                   |
| Dedic et al. (63)   | Yes         | N/A         | 53.78        | N/A                      | 4.19             | Serbians     | N/A                   |
| Delaye et al. (64)  | Yes         | N/A         | 66.5         | 0.42                     | N/A              | French       | N/A                   |
| Dorst et al. (43)   | Yes         | N/A         | 57.6         | N/A                      | 4.25             | German       | N/A                   |
| Dupuis et al. (42)  | Yes         | 57.5        | N/A          | N/A                      | N/A              | 1            | French                |
| Golomb et al. (65)  | N/A         | N/A         | 61.7         | N/A                      | N/A              | N/A          | American              |
| Hollinger et al. (66)| N/A        | N/A         | 60.1         | 2                        | 2.1              | Caucasian (57.4%) | N/A                                |
| Huang et al. (67)   | Yes         | 51.8        | 50.3         | 1.8                      | 3.1              | Chinese      | N/A                   |
| Huisman et al. (63) | Yes         | N/A         | 62.4         | N/A                      | N/A              | Dutch        | N/A                   |
| Kasarskis et al. (69)| Yes        | 58.7        | N/A          | N/A                      | N/A              | American     | N/A                   |
| Korner et al. (70)  | Yes         | 58.8        | N/A          | N/A                      | 3.5              | German       | N/A                   |
| Li et al. (71)      | Yes         | N/A         | 49           | N/A                      | N/A              | Chinese      | N/A                   |
| Mandrioli et al. (72)| Yes        | N/A         | 64.21        | N/A                      | 3.6              | Italian      | N/A                   |
| Mandrioli et al. (73)| Yes        | N/A         | 65.2         | N/A                      | N/A              | Italian      | N/A                   |
| Mariosa et al. (74) | N/A         | 53          | N/A          | N/A                      | 1                | Swedish (85%) | N/A                   |
| Millecamps et al. (75)| Yes      | 53          | N/A          | 4.4                      | 4.6              | Caucasian    | N/A                   |
| Miller et al. (76)  | N/A         | 48.8        | N/A          | N/A                      | N/A              | American (white 87.5%) | N/A                                |
| Moglia et al. (77)  | Yes         | N/A         | 66.4         | N/A                      | 3.6              | Italian      | N/A                   |
| Moreau et al. (78)  | N/A         | N/A         | 62.7         | N/A                      | 2.5              | French       | N/A                   |
| Mouazet et al. (79) | Yes         | N/A         | 61.9         | 2.9                      | N/A              | Caucasian    | N/A                   |
| Nieves et al. (80)  | Yes         | 63.2        | N/A          | N/A                      | N/A              | American     | N/A                   |
| Nunes et al. (81)   | Yes         | 69          | N/A          | N/A                      | N/A              | French       | N/A                   |
| Rafiq et al. (62)   | Yes         | 55          | N/A          | 2.3                      | N/A              | European     | N/A                   |
| Shelnor et al. (83) | Yes         | 53          | N/A          | 1.08                     | N/A              | American     | N/A                   |
| Suiteja et al. (51) | Yes         | 60-64       | N/A          | 3.5-2.6                  | 3.5-2.6          | Dutch        | N/A                   |
| Zinner et al. (84)  | Yes         | 63.7        | N/A          | N/A                      | N/A              | Canadian     | N/A                   |
| Wei et al. (85)     | Yes         | 55.4        | 54.5         | 1.48                     | N/A              | Chinese      | N/A                   |
| Mean                |             | 57.84       | 59.82        | 2.15                     | 2.88             |              |                       |

The table also shows the mean of ALS age, age of onset, duration of ALS and survival.

mentioned BMI (mean, 24.4). Moreover, only 20.7% declared any data in the matter of hypertension, 10.3% of cardiovascular risk, 10.3% of obesity, 13.78% of diabetes and 10.3% of glycaemia (Table 5). Regarding lipid metabolism (Table 6), more results were collected. Specifically, 31, 34.48, 34.48, and 41.4%, of the manuscripts show, respectively, TGL (mean, 4.13 mmol/L), LDL (mean, 5.40 mmol/L), HDL (mean, 2.21 mmol/L), and cholesterol (mean, 23.25 mmol/L). But, this information did not suffice to establish a correlation between ALS development and/or progression and metabolism alterations. In fact, 48.28% of the manuscripts evaluated show an association between factors (Table 7).

Additionally, to understand if the data outcome could be influenced by medication intake, prescriptions to ALS subjects were also investigated (Table 8). Around 20.7% of the studies mentioned that patients were under Riluzole™ treatment. Only one study stated that patients had been taking the medicine since diagnosis. About other prescriptions, 13.8% of the articles declared that ALS individuals were under cholesterol and hyperlipidaemia lowering agent therapy, or they were taking antioxidants taking antioxidants, antihypertensive, and antidiabetic agents.

**DISCUSSION**

Although several mechanisms are being related to ALS, its diagnosis occurs relatively late and, by then, 50% of neurons degenerated, and its prognosis is hard to predict (86). The lack of knowledge regarding secondary mechanisms related to the disease progression along with the limitation concerning studies enclosing individuals presenting ALS represents a struggle for the academic community. The development of strategies that could not only efficiently detect ALS onset but also predict its development and evaluate the therapeutic intervention, would
This systematic review show an association, meaning that this topic is still a matter of debate.

One of the first data that called the authors’ attention due to their strangeness was the presence (or not) of genetic mutation in ALS subjects; only 6.8% of the studies excluded fALS (Table 1). This means that 93.2% of articles put together all types of ALS patients in the same group. Such data indicate that clinical studies did not take into consideration the genetic background of investigated individuals. Hence, considering all ALS individuals as equals (fALS and sALS) could generate a considerable bias.

It is known that ALS patients have a distinct outcome and different age of onset and survival rate (48, 49). For that reason, it was suggested that such differences could be associated to environmental factors that, in turn, might influence ALS genes and duration (prognosis) (8, 87–95). Such aspects seem to include extreme physical activities, herbicide/pesticide exposure, neurotoxins, viral infection, prion disease, immune response, vascular risk factors and type 1 diabetes (8, 94, 95). On the other hand, diabetes type 2 in elderly, moderate physical activity, fat accumulation, and variations in glucose metabolism, high BMI and hypertension are described to be protective (94).

Nevertheless, studies about the relationship between diabetes and ALS have produced conflicting results. In young patients, diabetes is a consistent risk factor for ALS; in older patients, diabetes protects against ALS in Europe but increases the risk of ALS in Asia. Intriguingly, both environment and genotype might subsidize this discrepancy (94, 95).

Other parameters that are often mentioned in ALS patients’ studies, in an attempt to correlate ALS prognosis with survival, are patients’ age, age of onset and survival rate (that is calculated considering both previous factors) (Table 3). As previously shown, half of the manuscripts depicted patients’ age and the age of onset, making it hard to come to any conclusion concerning these factors. Besides, the exact meaning of “age of onset” contrast among works; in this review, two evaluated manuscripts declared its definition. Thus, future studies would be undoubtedly favored if the designation of onset was clear. Likewise, data interpretation would become easier, since results from different study centers could be comparable. Importantly, other groups also suggested that not only the onset but also sex ratio, age at diagnosis, comorbidities, and survival could be due to genetic background, predisposition, socio-economic status and patient’s ethnicity (89, 94, 96–100). Actually, we consider that ethnic group is essential for the interpretation of prognostic factors, as it relies (at least partially) on genetics and because it is known that several polymorphisms are population/ethnic-dependent and can modulate metabolism (96, 101–103). Oddly, only two of the evaluated manuscripts mentioned the words “Caucasian” and “white”, indicating that the ethnicity of ALS patients may not have been evaluated. Furthermore, in most reports, the study group is from the same country as the authors. Thus, some favoritism in the interpretation of clinical trials could be assumed.

It is well-known that ALS symptoms appear according to the group of affected neurons. For this reason, one can show changes in the upper or lower limbs (known as the spinal form of ALS) and/or can present dysphagia, dysphonia, or dysarthria.

| References | First motor signs (%) | ALSFRS |
|------------|-----------------------|--------|
| Chauvion et al. (52) | N/A | N/A |
| Chio et al. (48, 49) | 69.4 (S)/30.6 (B) | 30.2 |
| Chio et al. (41) | N/A | 37.4 |
| Dedic et al. (63) | 63.4 (S)/36.6 (B) | 40.6 |
| Delaye et al. (64) | 47 (S)/53 (B) | 30.1 |
| Dorst et al. (43) | 81.7 (L)/18.3 (B) | 36.2 |
| Dupuis et al. (42) | 75 (L)/25 (B) | N/A |
| Golomb et al. (65) | N/A | N/A |
| Hollinger et al. (66) | N/A | N/A |
| Huang et al. (67) | 77.7 (S)/22.3 (B) | 31.2 |
| Huisman et al. (69) | N/A | N/A |
| Kaisarskis et al. (69) | 72.5 (L)/26.3 (B)/1.2 (general) | 36.1 |
| Komer et al. (70) | 72 (S)/28 (B) | N/A |
| Li et al. (71) | N/A | N/A |
| Mandirici et al. (72) | 66 (S)/24 (B) | N/A |
| Mandirici et al. (73) | 69.8 (S)/30.2 (B) | N/A |
| Marisola et al. (74) | N/A | N/A |
| Millecampe et al. (75) | 93 (S)/7 (B) | N/A |
| Mitter et al. (76) | 95.3 (L)/4.7 (B) | N/A |
| Moglia et al. (77) | 68.8 (L)/31.2 (B) | 40.5 |
| Moreau et al. (78) | 73 (S)/29 (B) | 37 |
| Mouazet et al. (79) | 69 (L)/31 (B) | N/A |
| Nieves et al. (80) | 71.5 (S)/27.7 (B) | 37 |
| Nunes et al. (81) | 40.5 (S)/59.5 (B) | N/A |
| Rafiq et al. (82) | 79.3 (L)/19.7 (B) | 38.6 |
| Shefer et al. (83) | N/A | 38.4 |
| Suteja et al. (51) | 73–70 (S)/27–30 (B) | N/A |
| Zimran et al. (84) | 70 (S)/30 (B) | 37.7 |
| Wei et al. (85) | 79 (L)/21 (B) | 39.1 |
| Mean | 71.66 (S-L)/28 (B) | 36.4 |

The table also shows the mean of the most predominant motor symptoms and the mean of ALSFRS.
TABLE 5 | Smoking habits, BMI and metabolic parameters of ALS patients.

| References                  | Smoking | BMI   | Hypertension | Cardiovascular risk | Obesity | Diabetic | Glycaemia |
|-----------------------------|---------|-------|--------------|---------------------|---------|----------|-----------|
| Chaussenot et al. (62)      | N/A     | N/A   | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Chiò et al. (48, 49)        | N/A     | 25.1  | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Chiò et al. (41)            | N/A     | 24.5  | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Dedic et al. (63)           | N/A     | 26.74 | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Delaye et al. (64)          | 0       | 23.7  | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Dorst et al. (43)           | N/A     | 25.4  | N/A          | N/A                 | N/A     | 9.70%    | 6.23 mmol/L|
| Dupuis et al. (42)          | N/A     | 24.6  | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Golomb et al. (65)          | N/A     | N/A   | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Hollinger et al. (66)       | N/A     | N/A   | 36.90%       | N/A                 | N/A     | 9.10%    | 9%        |
| Huang et al. (67)           | N/A     | 21    | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Huismans et al. (69)        | 19.70%  | 25.7  | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Kasarskis et al. (69)       | All excluded | 27.1 | All excluded | N/A                 | All excluded | All excluded | N/A |
| Korner et al. (70)          | N/A     | N/A   | 31.50%       | N/A                 | N/A     | N/A      | N/A       |
| Li et al. (71)              | N/A     | N/A   | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Mandrioli et al. (72)       | N/A     | 24    | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Mandrioli et al. (73)       | N/A     | 24.5  | N/A          | N/A                 | N/A     | N/A      | 5.05 mmol/L|
| Mariosa et al. (74)         | N/A     | N/A   | N/A          | N/A                 | N/A     | N/A      | 4.98 mmol/L|
| Millecampes et al. (75)     | N/A     | N/A   | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Miller et al. (76)          | N/A     | N/A   | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Moglia et al. (77)          | N/A     | 24.3  | 45.50%       | 71.10%              | N/A     | 9.10%    | N/A       |
| Moreau et al. (78)          | 26%     | N/A   | 57%          | N/A                 | 20%     | 9%       | N/A       |
| Mouzat et al. (79)          | N/A     | N/A   | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Nieves et al. (80)          | N/A     | 26    | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Nunes et al. (81)           | N/A     | 21.6  | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Rafiq et al. (82)           | N/A     | 24.7  | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Shefner et al. (83)         | N/A     | 25.1  | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Sutedja et al. (51)         | 17%c−43%f| 25    | 26%          | 24% £               | 46%     | 5%       | N/A       |
| Zinman et al. (84)          | N/A     | 25.4  | N/A          | N/A                 | N/A     | N/A      | N/A       |
| Wei et al. (85)             | 31%     | 22    | 16.20%       | N/A                 | N/A     | N/A      | N/A       |
| Mean                        |         |        |              |                     |         |          |           |

The table also shows the mean of BMI. Some parameters found within the evaluated population were cardiovascular risk (c, events related), smoking habits (c, current or f, former), and BMI (#, baseline).

(symptoms correlated to the bulbar form). We demonstrated that 71.66% of ALS subjects presented the spinal form and 28% bulbar (Table 4). Although almost 30% of the manuscripts did not mention this factor, the results seem rather consistent among all research centers. Surprisingly, 48.3% of the studies monitored ALSFRS-R; such scale infers about the deterioration caused by the disorder and estimates disease progression per month (104). Considering that ALSFRS-R is world-wide accepted and that more than 50% of clinical evaluations did not cogitate them, the real estimation of ALS patients’ evolution is jeopardized, indicating that conclusions regarding any parameter based on clinical studies should be reviewed.

Despite the lack of homogeneity among the examined articles, and consequently, the absence of data that could support an accurate ALS evaluation, the authors further considered the smoking habits (one of the factors that often influence metabolism and patient survival) (Table 5). As already mentioned, 17.2% of all articles included smoking habits in their analysis. Considering that ALS subjects suffer from shortness of breath and that they must be under respiratory therapy throughout their lives, smoking should be determinant to patient’s quality of life, response to treatment, and survival.

Because metabolism is the central target of our review, specific parameters are shown in Tables 5–7. For BMI, 65.5% of all articles reported their values. On the other hand, hypertension, cardiovascular risk, obesity, diabetes, and glycaemia were less mentioned (<20%) (Table 5). About lipid metabolism, more results were gathered; around 35% of manuscripts described TGL, LDL, HDL and cholesterol levels (Table 6). However, available information is not enough to establish a direct link between ALS and metabolism alterations. In reality, less than half of the manuscripts evaluated show an association between both factors (Table 7). Nonetheless, it is worth mentioning that metabolism does influence ALS, but not in a unique manner. In fact, in literature, there is a debate about patients’ hypoad hypermetabolism. The so-called hypermetabolic condition
TABLE 6 | Blood tests outcome of ALS patients.

| References         | TGL       | LDL       | HDL       | Cholesterol | Hyperlipidemia |
|--------------------|-----------|-----------|-----------|-------------|----------------|
| Chaussenot et al.  | N/A       | N/A       | N/A       | N/A         | N/A            |
| Chiò et al. (48,49) | 6.38 mmol/L| 7.14 mmol/L| 3.29 mmol/L| 11.71 mmol/L| N/A            |
| Chiò et al. (41)   | N/A       | N/A       | N/A       | N/A         | N/A            |
| Dedic et al. (63)  | 1.87 mmol/L| 2.95 mmol/L| 1.37 mmol/L| 5.8 mmol/L  | N/A            |
| Delaye et al. (64) | N/A       | 3.64 mmol/L| 1.56 mmol/L| 6.51 mmol/L | N/A            |
| Dorst et al. (43)  | 1.77 mmol/L| 3.87 mmol/L| 1.29 mmol/L| 6 mmol/L    | N/A            |
| Dupuis et al. (42) | 10.06 mmol/L| 12.39 mmol/L| 4.64 mmol/L| 193.62 mmol/L| N/A            |
| Golomb et al. (65) | N/A       | N/A       | N/A       | N/A         | N/A            |
| Hollinger et al. (66)| N/A    | N/A       | N/A       | N/A         | 26.30%         |
| Huang et al. (67)  | 7.07 mmol/L| 5.99 mmol/L| 2.56 mmol/L| 11.23 mmol/L| N/A            |
| Huisman et al. (69)| N/A       | N/A       | N/A       | N/A         | N/A            |
| Kiasarskis et al. (69)| N/A   | N/A       | N/A       | N/A         | All excluded   |
| Kern et al. (70)   | N/A       | N/A       | N/A       | N/A         | N/A            |
| Li et al. (71)     | N/A       | N/A       | N/A       | N/A         | N/A            |
| Mandrioli et al. (72)| N/A    | N/A       | N/A       | N/A         | N/A            |
| Mandrioli et al. (73)| 5.5 mmol/L| 7.21 mmol/L| 2.7 mmol/L| 10.98 mmol/L| N/A            |
| Mariosa et al. (74)| 1.33 mmol/L| 3.69 mmol/L| 1.52 mmol/L| 5.58 mmol/L | N/A            |
| Milicamps et al. (75)| N/A    | N/A       | N/A       | N/A         | N/A            |
| Miller et al. (76) | N/A       | N/A       | N/A       | N/A         | N/A            |
| Moglia et al. (77) | N/A       | N/A       | N/A       | N/A         | N/A            |
| Moreau et al. (78) | N/A       | N/A       | N/A       | N/A (32%)   | N/A            |
| Mouzat et al. (79) | N/A       | N/A       | N/A       | N/A         | N/A            |
| Nieves et al. (80) | N/A       | N/A       | N/A       | N/A         | N/A            |
| Nunes et al. (81)  | N/A       | N/A       | N/A       | 11.32 mmol/L| N/A            |
| Rafiq et al. (82)  | 1.6 mmol/L| 3.8 mmol/L| 1.5 mmol/L| 5.9 mmol/L  | N/A            |
| Sheffner et al. (83)| N/A     | N/A       | N/A       | N/A         | N/A            |
| Sutedja et al. (51) | N/A    | 3.3 mmol/L| 1.7 mmol/L| 5.7 mmol/L  | N/A            |
| Zinman et al. (84) | N/A       | N/A       | N/A       | N/A         | N/A            |
| Wei et al. (85)    | 1.6 mmol/L| N/A       | N/A       | 4.7 mmol/L  | N/A            |
| MEAN               | 4.13 mmol/L| 5.40 mmol/L| 2.21 mmol/L| 23.25 mmol/L|                |

is correlated with an augmentation in the energy expenditure to maintain mobility and ventilation avoiding, as a consequence, weakness and exhaustion of the remaining innervated muscles (105–108). Moreover, in an attempt to avoid an increase in oxidative stress, it is suggested that mitochondria become uncoupled ensuing in hypermetabolism (109, 110). Thus, the high resting metabolism could be activated to maintain energetic status. Because of that, hyperlipidaemia and increments in gluconeogenesis, lipolysis and ketogenesis pathways are sighted as neuroprotective (106–108, 111, 112). Interestingly, it was observed a hypolipidemia state in the pre-symptomatic ALS mouse model, in addition to changes in complex lipids during the first phase of motor symptoms (113, 114). Nonetheless, it was also reported that alterations in metabolism, exactly in the lumbar spinal cord in the SOD1G93A mice model before motor symptoms, are primarily caused by the mutation itself than a function of ALS’s course (115).

However, it is important to stress that this is not a consensus in the literature and it is defiance for the knowledge of ALS neuropathology (116). Indeed, Chiò et al. described that there was not any effect of metabolism on survival (48, 49), although they suggested that dietetic habits could account for differences in phenotypes and disease progression (48, 49). This hypothesis, by the way, is in accordance with several reports that suggest that hypermetabolism seems to be interconnected with a predisposition of ALS subjects to malnutrition as a result of fear of choking and aspiration, dysphagia and inability to feed themselves (58, 117, 118). It was also shown in vivo FDG-PET study performed with C9orf72 mutation’s patients that brain hypometabolism was consistent with ALS clinical phenotypes (119). Moreover, Cedarbaum et al. indicated that such inconsistencies may also be related to the insufficiency relevant information of ALSFRS-R subscale to estimate physical activity (120). Hence, no conclusion involving these parameters should be regarded either.

Because it is known that some medication also modifies cellular metabolism, we also considered ALS subjects’ prescriptions in our analysis (Table 8). We observed that (i) 13.8% of articles declared that patients were taking antioxidants, antihypertensive and/or anti-diabetic drugs, in addition to
TABLE 7 | Summary of the correlation between metabolic parameters and ALS course and prognosis.

| References          | Presence of association | No association | N/A | Metabolic parameter                                      |
|---------------------|-------------------------|----------------|-----|----------------------------------------------------------|
| Chaussenot et al. (62) | ✓                       |                |     | Hyperlipidemia                                           |
| Chio et al. (48, 49) | ✓                       | ✓              |     | Creatinine levels                                        |
| Dedic et al. (63)   | ✓                       | ✓              |     | Hyperlipidemia                                           |
| Delaye et al. (64)  | ✓                       |                 |     | Dyslipidemia                                              |
| Dorst et al. (43)   | ✓                       |                 |     | Elevated triglyceride and cholesterol                    |
| Dupuis et al. (42)  | ✓                       |                 |     | Hyperlipidemia                                           |
| Golomb et al. (65)  | ✓                       |                 |     | Antecedent hypertension and hyperlipidemia               |
| Hollinger et al. (66) | ✓                       | ✓              |     | Low premorbid BMI and a high fat intake                   |
| Huang et al. (67)   | ✓                       |                 |     | Cardiovascular diseases or risk factors                  |
| Kasarskis et al. (69) | ✓                       |                 |     | Body composition                                          |
| Kornet et al. (70)  | ✓                       |                 |     | Increase of triglycerides                                |
| Li et al. (71)      | ✓                       |                 |     | Hypertension and heart diseases                           |
| Mandrioli et al. (72) | ✓                       |                 |     | Imbalance between apoB and apoA-I, and LDL-C and HDL-C   |
| Mandrioli et al. (73) | ✓                       |                 |     | Hypertension, type 2 diabetes and cardiovascular risk factors |
| Marossedas et al. (74) | ✓                      |                 |     | Lipid profile                                             |
| Millecamps et al. (75) | ✓                       |                 |     | Vascular risk factors                                    |
| Miller et al. (76)  | ✓                       |                 |     | Higher BMI                                                |
| Moglia et al. (77)  | ✓                       |                 |     | Hyperlipidemia                                            |
| Moreau et al. (78)  | ✓                       |                 |     | Higher levels of HbA1c, but not fasting blood glucose concentrations |
| Mouzat et al. (79)  | ✓                       |                 |     | Hyperlipidemia                                            |
| Nieves et al. (80)  | ✓                       |                 |     | Lipid profile                                             |
| Nunes et al. (81)   | ✓                       |                 |     | Vascular risk factors                                    |
| Rafiq et al. (82)   | ✓                       |                 |     | Vascular risk factors                                    |
| Shefner et al. (83) | ✓                       |                 |     | Vascular risk factors                                    |
| Sutedja et al. (51) | ✓                       |                 |     | Vascular risk factors                                    |
| Zinman et al. (84)  | ✓                       |                 |     | Vascular risk factors                                    |

**Limitations of the Study**

Several factors might have contributed to the data generated and showed in this review. In fact, numerous methodological limitations of previous works must be listed, i.e., system used by primary centers to acquire evidence, population evaluated (representative vs. available), single-centered vs. multicentric study, sample size, study duration, gene mutation, familial vs. sporadic ALS cases, ethnicity, genetic background, environmental exposure to risk factors, incomplete ALSFRS-R (or the absence of it) and type of study (prospective vs. retrospective; the last can be inaccurate due to lack of data and even lack of patient, in addition to an indisposition of relatives to corroborate with some information) (73). Likewise, in the most of published studies, there were also significant discrepancies regarding age of onset, sex ratio and dose/time of pharmacological therapies. Still, authors believe that there is no sufficient data to perform a meaningful meta-analysis and, therefore, establish a correlation with ALS. Also, a prospective study with an in-depth examination of ALS patients could be supportive.
### TABLE 8 | Medication taken by ALS patients.

| References            | ALS medication | For how long | Medication (other)       |
|-----------------------|----------------|--------------|--------------------------|
| Chausse not et al. (62)| N/A            | N/A          | N/A                      |
| Chiò et al. (45, 49)  | Riluzole (9%)  | N/A          | N/A                      |
| Chio et al. (41)      | N/A            | N/A          | N/A                      |
| Dedic et al. (63)     | N/A            | N/A          | N/A                      |
| Delaye et al. (64)    | Riluzole (all)| From diagnosis| Tocopherol and cholesterol lowering agents |
| Dorst et al. (43)     | N/A            | N/A          | Simvastatin              |
| Dupuis et al. (42)    | N/A            | N/A          | N/A                      |
| Golomb et al. (65)    | N/A            | N/A          | Hyperlipidaemia lowering agent |
| Hollinger et al. (66) | N/A            | N/A          | N/A                      |
| Huang et al. (67)     | N/A            | N/A          | N/A                      |
| Huisman et al. (69)   | N/A            | N/A          | N/A                      |
| Kasarskis et al. (69) | N/A            | N/A          | N/A                      |
| Korner et al. (70)    | N/A            | N/A          | N/A                      |
| Li et al. (71)        | N/A            | N/A          | N/A                      |
| Mandrioli et al. (72) | N/A            | N/A          | N/A                      |
| Mandrioli et al. (73) | Riluzole (94.2%)| N/A         | N/A                      |
| Mariosa et al. (74)   | N/A            | N/A          | N/A                      |
| Millecamps et al. (75)| N/A            | N/A          | N/A                      |
| Miller et al. (76)    | N/A            | N/A          | N/A                      |
| Moglia et al. (77)    | N/A            | N/A          | N/A                      |
| Moreau et al. (78)    | N/A            | N/A          | N/A                      |
| Mouzat et al. (79)    | N/A            | N/A          | N/A                      |
| Nieves et al. (80)    | N/A            | N/A          | N/A                      |
| Nunes et al. (81)     | N/A            | N/A          | N/A                      |
| Ralifq et al. (82)    | N/A            | N/A          | N/A                      |
| Shefner et al. (83)   | N/A            | N/A          | N/A                      |
| Sutedja et al. (51)   | N/A            | N/A          | Antihypertensive (26%), Antidiabetic (5%) |
| Zinman et al. (84)    | Riluzole (82%) | N/A          | N/A                      |
| Wei et al. (85)       | N/A            | N/A          | N/A                      |

**Conclusion**

Our review points to two main conclusions based on recent developments, (i) there is no assertive data available in the literature to establish a specific link between metabolic parameters and the progression and survival of ALS, and (ii) metabolism does influence ALS, but not in a unique manner. This means that some pathways can be related to it and can modulate ALS outcome, but the complete via and its regulation are not well-defined yet. Furthermore, our conclusions can be an alert about how researchers conduct their investigation and how epidemiology studies are designed, since the effort that is being made toward the establishment and validation of a clinical biomarker seems to occur in vain, given the data inconsistency, database divergences, and the absence, in most papers, of relevant information. Essentially, which are the factors, other than the ones mentioned herein, which should be revisited? We believe that investigators should consider exploring other factors, as food habits, neurodevelopment deficits, complications at birth and mother's infection and hypertension (all aspects already correlated to brain development and function). It is worth mentioning that all the topics above can induce modifications in cellular homeostasis through fluctuations in mitochondrial function, ATP synthesis, gene transcription and/or epigenetic regulation. Considering that all these features can also be modulated by genotype background (mutations, polymorphisms), ethnic group, behavioral habits, and environmental factors, ALS's etiology is far more complicated and heterogeneous than we presume (8, 92, 94, 95, 129). Moreover, we should also consider the role of microbiota. Indeed, it was already demonstrated in recent reports that gut microbiota modulates inflammation through short-chain fatty acids and endotoxin synthesis. The microbiota is correlated not only with Alzheimer's disease, neuromyelitis optica, multiple sclerosis, and Parkinson's disease but also ALS (130, 131).

Thus, to provide a reliable record, it is suggested a public policy in which all research and clinical centers might assess the parameters discussed herein. In accordance, Martin et al. in 2016 also recommended a collaborative study involving a wide international consortium to investigate, using a standard methodology, the link between ancestry, environment and ALS phenotype (129). Moreover, the authors genuinely suggest that all conclusions based on clinical trials and patients' evaluation to date should be reconsidered. Accordingly, this systematic review attempts to provide a comprehensible database to facilitate multicentered collaboration, validation, and ultimately, clinical translation.

**DATA AVAILABILITY STATEMENT**

All data generated or analyzed during this study are included in the article/supplementary material.

**AUTHOR CONTRIBUTIONS**

TR and MB analyzed all the articles’ titles and abstracts. The defined articles were randomly divided by all authors (GS, MB, ET, BA, and TR), and TR and MC double read all of them. TR wrote the manuscript, and both TR and MC revised it. All authors approved the final version.

**FUNDING**

This work was supported by São Paulo Research Foundation (FAPESP) (ref. 2015/02041-1) and Research Support Foundation of Santa Casa de São Paulo School of Medical Science (FCCMSCSP) (2017–2019). MB was supported by Master CAPES and FAPESP (2016/12039-7). GS was an undergraduate medical student. ET was under a CAPES Master fellowship program. BA was supported by IC/FAPESP (2018/09084-6).
REFERENCES

1. D’Alessandro G, Calcagno E, Tartari S, Rizzardini M, Ivernizzi RW, Cantoni L. Glutamate and glutathione interplay in a motor neuronal model of amyotrophic lateral sclerosis reveals altered energy metabolism. Neurobiol Dis. (2011) 43:346–55. doi: 10.1016/j.nbd.2011.04.003

2. Bozzo E, Mirra A, Carri MT. Oxidative stress and mitochondrial damage in the pathogenesis of ALS: new perspectives. Neurosci Lett. (2017) 636:3–8. doi: 10.1016/j.neulet.2016.04.065

3. Saberi S, Stauffer JE, Schulte DJ, Ravits J. Neuropathology of amyotrophic lateral sclerosis and its variants. Neuro Clin. (2015) 33:855–76. doi: 10.1016/j.ncl.2015.07.012

4. Cozzolino M, Carri MT. Mitochondrial dysfunction in ALS. Prog Neurobiol. (2012) 97:54–6. doi: 10.1016/j.pneurobio.2011.06.003

5. Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. (2006) 253:1642–3. doi: 10.1007/s00415-006-0195-y

6. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JL, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Nature. (2011) 479:223–7. doi: 10.1038/nature10372

7. Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, et al. A comprehensive review of amyotrophic lateral sclerosis. Acta Neuropathol. (2012) 124:339–52. doi: 10.1007/s00401-012-1022-4

8. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. (2001) 344:1688–700. doi: 10.1056/NEJM200105313442207

9. Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet. (2005) 75:933–47. doi: 10.1086/426001

10. Martin LJ, Liu Z. Opportunities for neuroprotection in ALS using cell loss prevention mechanisms. Drug Discov Today Dis Model. (2004) 1:135–43. doi: 10.1016/j.ddmod.2004.09.004

11. Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH. Oxidative stress and mitochondrial damage in motor neurons and osteopontin, and blunted inflammatory responses in ALS rats. J Neurol Neurosurg Psychiatry. (2011) 82:1069–75. doi: 10.1136/jnnpd.2010.203007

12. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole in amyotrophic lateral sclerosis. Antioxid Redox Signal. (2008) 10:405–43. doi: 10.1089/ars.2007.1760

13. Bozzo F, Mirra A, Carri MT. Oxidative stress and mitochondrial damage in the pathogenesis of ALS: new perspectives. Neurosci Lett. (2015) 636:3–8. doi: 10.1016/j.neulet.2016.04.065

14. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JL, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Nature. (2011) 479:223–7. doi: 10.1038/nature10372

15. Nikodemova M, Small AL, Smith SM, Mitchell GS, Watters JJ. Spinal but not cortical microglia acquire an atypical phenotype with high VEGF, galec tin-3 and osteopontin, and blunted inflammatory responses in ALS rats. J Neurol Neurosurg Psychiatry. (2011) 82:1069–75. doi: 10.1136/jnnpd.2010.203007

16. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JL, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Nature. (2011) 479:223–7. doi: 10.1038/nature10372

17. Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, et al. Neuroprotection in amyotrophic lateral sclerosis in mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. (1995) 92:689–93. doi: 10.1073/pnas.92.3.689

18. Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. (1994) 264:1772–5. doi: 10.1126/science.2802958

19. Rippis ME, Huntley GW, Harts PR, Morrison JH, Gordon JW. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. (1995) 92:689–93. doi: 10.1073/pnas.92.3.689

20. Nonneman A, Czemi N, Lewandowski SA, Nuyts R, Thal DR, Pfrieger FW, et al. Astrocyte-derived Jagged-1 mitigates deleterious Notch signaling in amyotrophic lateral sclerosis. Neurobiol Dis. (2018) 119:26–40. doi: 10.1016/j.nbd.2018.07.012
40. Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? *Lancet Neurol.* (2014) 13:1127–38. doi: 10.1016/S1474-4422(14)70129-2

41. Chiò A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmazoi F, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine in prognostic study. *JAMA Neurol.* (2014) 71:134–42. doi: 10.1001/jamaneurol.2014.1129

42. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JI, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. *Neurology.* (2008) 70:1004–9. doi: 10.1212/01.wnl.0000285800.70324.27

43. Dorst J, Kuhnlein P, Hendrich C, Kassubeck I, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. *J Neurol.* (2011) 258:613–7. doi: 10.1007/s00415-010-5805-z

44. Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urine, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. *Disabil Rehabil.* (2012) 51:1501–8. doi: 10.2169/internalmedicine.51.7465

45. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. *Amyotrophic Lateral Scler Other Motor Neuron Disord.* (2005) 6:37–44. doi: 10.1080/14660820510270235

46. Gonzalez de Aguilar JL, Dupuis L, Oudart H, Loeffler JP. The metabolic hypothesis in amyotrophic lateral sclerosis: insights from mutant Cu/Zn-superoxide dismutase mice. *Biomed Pharmacother.* (2005) 59:190–6. doi: 10.1016/j.biopha.2005.03.003

47. Yang JW, Kim SM, Kim HJ, Kim JE, Park KS, Kim SH, et al. Hypolipidemia in patients with amyotrophic lateral sclerosis: a possible gender difference? *J Clin Neurol.* (2013) 9:125–9. doi: 10.3988/jcn.2013.9.2.125

48. Chiò A, Calvo A, Ilardi A, Cavallio E, Moglia C, Mutani R, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. *Neurology.* (2009) 73:1681–5. doi: 10.1212/WNL.0b013e3181c1dfe1

49. Chiò A, Logroscino G, Haridion G, Swisgler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: A critical review. *Amyotrophic Lateral Scler.* (2009) 10:310–23. doi: 10.3190/174829608025666824

50. Pagnoni S, Zhang M, Quiriot Zärate A, Jaffa M, Yu H, Cudkowicz ME, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. *J Neurol.* (2012) 259:1923–8. doi: 10.1007/s00415-012-6440-7

51. Sutedja NA, van der Schouw YT, Fischer K, Sizoo EM, Huisman MH, de Vries JH, et al. Serum lipid levels are related to respiratory impairment in patients with ALS. *J Neurol Sci.* (2012) 310:14–7. doi: 10.1016/j.jns.2012.07.019

52. Golomb BA, Kwon EK, Koporski S, Evans MA. Amyotrophic lateral sclerosis-like conditions in possible association with cholestrol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. *Drug Saf.* (2009) 32:649–61. doi: 10.2165/00002018-200932080-00004

53. Hollinger SK, Okosun IS, Mitchell CS. Antecedent disease and amyotrophic lateral sclerosis: what is protecting whom? *Front Neurol.* (2016) 7:47. doi: 10.3389/fneur.2016.00047

54. Huong R, Guo X, Chen X, Zheng Z, Wei Q, Cao B, et al. The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a meta-analysis. *Amyotrophic Lateral Scler Frontotemporal Degener.* (2015) 16:359–65. doi: 10.1039/c5at00007b

55. Huisman MH, Seelen M, van Doornaal PT, de Jong SW, de Vries JH, van der Kooi AJ, et al. Effect of presymptomatic body mass index and consumption of fat and alcohol on amyotrophic lateral sclerosis. *JAMA Neurol.* (2015) 72:115–62. doi: 10.1001/jamaneurol.2015.1584

56. Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, et al. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. *Am J Clin Nutr.* (2014) 99:782–803.

57. Konner S, Kollew K, Iseman J, Muller-Heine A, Dengler R, Krampf K, et al. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. *Eur J Neurol.* (2013) 20:647–54. doi: 10.1111/ene.12015

58. Li XL, Shu S, Li XG, Liu Q, Liu F, Cui B, et al. CHCHD10 is not a frequent causative gene in Chinese ALS patients. *Amyotrophic Lateral Scler Frontotemporal Degener.* (2016) 17:458–60. doi: 10.3109/21678421.2016.1170151

59. Mandrioli J, Ferri L, Fasano A, Zucchi E, Fini N, Moglia C, et al. Screening of CHCHD10 in a French cohort confirms the involvement of this gene in frontotemporal dementia with amyotrophic lateral sclerosis patients. *Neurobiol Aging.* (2014) 35:2884. doi: 10.1016/j.neurobiolaging.2014.07.022

60. Marois D, Hammar N, Malmsstrom H, Ingre C, Jungner I, Ye W, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. *Ann Neurol.* (2017) 81:718–28. doi: 10.1002/ana.24936

61. Millecamps S, Salachas F, Cazenave C, Gordon P, Bricka B, Camuzat A, et al. SOD1, ANG, VAPB, TARDBP and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. *J Med Genet.* (2010) 47:554–60. doi: 10.1136/jmg.2010.077180
76. Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, et al. An aspartic oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase I, randomised, first-in-man study. Lancet Neurol. (2013) 12:435–42. doi: 10.1016/S1474-4422(13)70061-9

77. Moglia C, Cava A, Graziano A, Bertuzzo D, Cugnasco P, Solero L, et al. Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:590–7. doi: 10.1080/21678421.2017.1336560

78. Moreau C, Brunaud-Danel V, Dalongeville J, Duhamel A, Laurier-Grymonprez L, de Reuck J, et al. Modifying effect of arterial hypertension on amyotrophic lateral sclerosis. Amyotroph Lateral Scler. (2012) 13:194–201. doi: 10.3109/17482968.2011.610110

79. Mouzat K, Molinari N, Kantar J, Polge A, Corcia P, Couratier P, et al. Liver X receptor genes variants modulate ALS phenotype. Mol Neurobiol. (2018) 55:1959–65. doi: 10.1007/s12051-017-0453-2

80. Nieves JW, Gennings C, Factor-Litvak P, Hufp J, Singleton J, Shaf V, et al. Association between dietary intake and function in amyotrophic lateral sclerosis. JAMA Neurol. (2016) 73:1425–32. doi: 10.1001/jamaneurol.2016.3401

81. Nunes G, Santos CA, Grunho M, Fonseca J, Enteral feeding through endoscopic gastrostomy in amyotrophic lateral sclerosis patients. Nutr Hosp. (2016) 33:561. doi: 10.20960/nh.561

82. Paez-Colasante X, Figueroa-Romero C, Sakowski SA, Goutman SA, Feldman EL. Amyotrophic lateral sclerosis: mechanisms and therapeutic therapeutics in the epigenomic era. Neural Regen Res. (2015) 10:75–82. doi: 10.1016/j.ncl.2015.07.009

83. Rouas F, Le Moine N, Corcia P, Couratier P, et al. Modifying effect of arterial hypertension on amyotrophic lateral sclerosis. Lancet Neurol. (2017) 31:7–19. doi: 10.1016/S1474-4422(16)30146-7

84. Ruschel SM, Kim H, Kim JE, Park KS, Sung JJ, Kim SH, et al. Amyotrophic lateral sclerosis. Am J Clin Nutr. (2004) 79:328–34. doi: 10.1093/ajcn/79.3.328

85. Scialdone R, H错过is J, Hulanski ML, Caputo M, Fortuny L, Pratx LB, et al. Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations. BMC Genetics. (2015) 16:93. doi: 10.1186/s12863-015-0255-3

86. Shen N, Luo CJ, Hou WH, Li CY. Risk of amyotrophic lateral sclerosis in patients with diabetes: a nationwide population-based cohort study. J Epidemiol. (2015) 25:445–51. doi: 10.2188/jea.JE20140176
118. Desport JC, Torny F, Lacoste M, Preux PM, Couratier P. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. *Neurodegener Dis.* (2005) 2:202–7. doi: 10.1159/000089626

119. Castelnovo V, Caminiti SF, Riva N, Magnani G, Silani V, Perani D. Heterogeneous brain FDG-PET metabolic patterns in patients with C9orf72 mutation. *Neurrol Sci.* (2019) 40:515–21. doi: 10.1007/s10072-018-3685-7

120. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase III). *J Neurol Sci.* (1999) 169:13–21. doi: 10.1016/S0022-510X(99)00210-5

121. Umemiya M, Berger AJ. Inhibition by riluzole of glycinergic postsynaptic currents in rat hypoglossal motoneurones. *Br J Pharmacol.* (1995) 116:3227–30. doi: 10.1111/j.1476-5381.1995.tb15128.x

122. Centonze D, Calabresi P, Pisani A, Marinelli S, Marfia GA, Bernardi G. Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. *Neuropharmacology.* (1998) 37:1063–70. doi: 10.1016/S0028-3908(98)00081-1

123. Zona C, Cavalcanti S, De Sarro G, Siniscalchi A, Marchetti C, Gaetti C, et al. Kainate-induced currents in rat cortical neurons in culture are modulated by riluzole. *Synapse.* (2002) 43:244–51. doi: 10.1002/syn.10040

124. Pereira AC, Lambert HK, Grossman YS, Dumitriu D, Waldman R, Jannetty SK, et al. Glutamatergic regulation prevents hippocampal dependent age-related cognitive decline through dendritic spine clustering. *Proc Natl Acad Sci USA.* (2014) 111:18733–8. doi: 10.1073/pnas.1421285111

125. Frizzo ME, Dall’Onder LP, Dalcin KB, Souza DO. Riluzole enhances glutamate uptake in rat astrocyte cultures. *Cell Mol Neurobiol.* (2004) 24:123–8. doi: 10.1023/B:CEMN.0000012717.37839.07

126. Fumagalli E, Funicello M, Rauen T, Gobbi M, Mennini T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. *Eur J Pharmacol.* (2008) 578:171–6. doi: 10.1016/j.ejphar.2007.10.023

127. Dash RP, Babu RJ, Srinivas NR. Two decades-long journey from riluzole to edaravone: revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics. *Clin Pharmacokinet.* (2018) 57:1385–98. doi: 10.1007/s40262-018-0653-4

128. Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. *Med Res Rev.* (2019) 39:733–48. doi: 10.1002/med.21528

129. Marin B, Logroscino G, Boumèdiène É, Labrunie A, Couratier P, Babron MC, et al. Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. *Eur J Epidemiol.* (2016) 31:229–45. doi: 10.1007/s10654-015-0090-x

130. Castillo-Alvarez F, Marzo-Sola ME. Role of the gut microbiota in the development of various neurological diseases. *Neurologia.* (2019). doi: 10.1016/j.nrl.2019.03.017. [Epub ahead of print].

131. Zhai CD, Zheng JI, An BC, Huang HF, Tan ZC. Intestinal microbiota composition in patients with amyotrophic lateral sclerosis: establishment of bacterial and archaeal communities analyses. *Clin Med J (Engl).* (2019) 132:1815–22. doi: 10.1097/CM9.0000000000000351

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Brito, da Silva, Tilieri, Araujo, Calió and Rosenstock. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.